Agennix raises €76 million
This article was originally published in Scrip
Raising substantial sums of money is always easier when a company has a wealthy benefactor supporting its aims. Agennix, the German cancer research company, has raised €76 million through a rights and subscription issue that was heavily backed by dievini Hopp BioTech Holding, the life sciences-focused investment business. The funds will be used mainly to finance the company's Phase III trials of talactoferrin, the company's recombinant human lactoferrin.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.